Recently, it was demonstrated that the abundance of CD16+ fibroblasts in HER2+ breast cancer patients is correlated with poor response to trastuzumab through severe desmoplasia and inefficient drug delivery. The gene discussed is ERBB2; the disease is breast cancer.